Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

CVT 510

Known as: CVT-510 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Termination of Paroxysmal Supraventricular Tachycardia by Tecadenoson (CVT-510), a Novel A1-Adenosine Receptor Agonist Eric N… 
  • figure 1
  • table 1
  • table 2
2013
2013
Selective pharmacological activation of the adenosine 1 receptor (A1R) is a promising new approach to achieve a potent block of… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2010
2010
Publication of this article is suspended until the authors can provide full identification and verification of the chemical… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2003
2003
OBJECTIVES The aim of this study was to evaluate tecadenoson safety and efficacy during conversion of paroxysmal supraventricular… 
Review
2003
Review
2003
Adenosine is an endogenous nucleoside that has potent antiarrhythmic effects on paroxysmal supraventricular tachycardia (PSVT… 
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2003
2003
Elevated serum nonesterified free fatty acid (NEFA) concentrations are detrimental to both the mechanical and electrical function… 
  • figure 1
  • figure 3
  • figure 2
  • figure 5
  • figure 4
Review
2002
Review
2002
  • A. Zaza
  • Current opinion in investigational drugs
  • 2002
  • Corpus ID: 33013187
CVT-510, the lead compound from a series of selective adenosine A1 receptor agonists, is being developed by CV Therapeutics for… 
2001
2001
Background: CVT-510, N-(3(R)-tetrahydrofuranyl)-6-aminopurine riboside, is a selective A,-adenosine receptor agonist with… 
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2001
2001
CVT‐510 (N‐(3(R)‐tetrahydrofuranyl)‐6‐aminopurine riboside), a selective A1 adenosine receptor (AdoR) agonist, is being developed… 
1999
1999
The purpose of this study was to compare the pharmacological properties (i.e. the AV nodal depressant, vasodilator, and inotropic…